Biofrontera Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 3/6

Biofrontera has a total shareholder equity of $10.9M and total debt of $296.0K, which brings its debt-to-equity ratio to 2.7%. Its total assets and total liabilities are $21.6M and $10.7M respectively.

Anahtar bilgiler

2.7%

Borç/özkaynak oranı

US$296.00k

Borç

Faiz karşılama oranın/a
NakitUS$4.39m
EşitlikUS$10.91m
Toplam yükümlülüklerUS$10.66m
Toplam varlıklarUS$21.57m

Son finansal sağlık güncellemeleri

Can Biofrontera (NASDAQ:BFRI) Afford To Invest In Growth?

Oct 18
Can Biofrontera (NASDAQ:BFRI) Afford To Invest In Growth?

Recent updates

Biofrontera Inc.'s (NASDAQ:BFRI) Shares Leap 25% Yet They're Still Not Telling The Full Story

Sep 28
Biofrontera Inc.'s (NASDAQ:BFRI) Shares Leap 25% Yet They're Still Not Telling The Full Story

Further Upside For Biofrontera Inc. (NASDAQ:BFRI) Shares Could Introduce Price Risks After 40% Bounce

Aug 09
Further Upside For Biofrontera Inc. (NASDAQ:BFRI) Shares Could Introduce Price Risks After 40% Bounce

Take Care Before Jumping Onto Biofrontera Inc. (NASDAQ:BFRI) Even Though It's 29% Cheaper

May 24
Take Care Before Jumping Onto Biofrontera Inc. (NASDAQ:BFRI) Even Though It's 29% Cheaper

Biofrontera Inc. (NASDAQ:BFRI) Not Doing Enough For Some Investors As Its Shares Slump 28%

Dec 30
Biofrontera Inc. (NASDAQ:BFRI) Not Doing Enough For Some Investors As Its Shares Slump 28%

The Market Doesn't Like What It Sees From Biofrontera Inc.'s (NASDAQ:BFRI) Revenues Yet As Shares Tumble 43%

Nov 13
The Market Doesn't Like What It Sees From Biofrontera Inc.'s (NASDAQ:BFRI) Revenues Yet As Shares Tumble 43%

Can Biofrontera (NASDAQ:BFRI) Afford To Invest In Growth?

Oct 18
Can Biofrontera (NASDAQ:BFRI) Afford To Invest In Growth?

Biofrontera announces preliminary Q3 product revenue, stock falls ~7% after hours

Oct 05

Biofrontera gets notice of allowance for U.S. patent covering a nanoemulsion formulation

Sep 06

Biofrontera GAAP EPS of -$0.05, revenue of $4.5M; reaffirms FY22 guidance

Aug 12

Biofrontera announces 2Q prelim product revenues

Jul 12

Finansal Durum Analizi

Kısa Vadeli Yükümlülükler: BFRI's short term assets ($17.5M) exceed its short term liabilities ($9.3M).

Uzun Vadeli Yükümlülükler: BFRI's short term assets ($17.5M) exceed its long term liabilities ($1.4M).


Borç-Özkaynak Tarihçesi ve Analizi

Borç Seviyesi: BFRI has more cash than its total debt.

Borcun Azaltılması: Insufficient data to determine if BFRI's debt to equity ratio has reduced over the past 5 years.


Bilanço


Nakit Pist Analizi

Geçmişte ortalama olarak zarar eden şirketler için, en az 1 yıllık nakit akışına sahip olup olmadıklarını değerlendiriyoruz.

İstikrarlı Nakit Pisti: BFRI has less than a year of cash runway based on its current free cash flow.

Tahmini Nakit Akışı: BFRI has less than a year of cash runway if free cash flow continues to reduce at historical rates of 4.6% each year


Sağlıklı şirketleri keşfedin